/PRNewswire/ Juniper Biologics Pte Ltd, a science-led healthcare company focused on researching, developing and commercializing novel therapies, and Helsinn.
Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets Lugano, Switzerland, and Singapore, 04 May 2022 - Juniper
Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets* - PRN India News webindia123.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webindia123.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Juniper Biologics, a science-led healthcare company focused on researching, developing and commercializing novel therapies announced today that.